- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 129-143 of
901 results
2110 Exhibit: EX2110 Verges, B and Charbonnel, B, After the LEADER trial and SU...
Document
IPR2023-00724, No. 2110 Exhibit - EX2110 Verges, B and Charbonnel, B, After the LEADER trial and SUSTAIN 6, how do we explain the cardiovascular benefits of some GLP 1 receptor agonis...
|
|
Cite Document
3001 Exhibit: Exhibit 3001
Document
IPR2024-00631, No. 3001 Exhibit - Exhibit 3001 (P.T.A.B. Mar. 11, 2024)
|
|
Cite Document
2535 Exhibit: EX2535 Declaration of Jenny C Wu
Document
IPR2023-00724, No. 2535 Exhibit - EX2535 Declaration of Jenny C Wu (P.T.A.B. Apr. 10, 2024)
|
|
Cite Document
1006 Exhibit: 1006 CV of William J Jusko, PhD
Document
IPR2024-00631, No. 1006 Exhibit - 1006 CV of William J Jusko, PhD (P.T.A.B. Mar. 1, 2024)
|
|
Cite Document
1001 Exhibit: 1001 US Patent No 10,335,462
Document
IPR2024-00631, No. 1001 Exhibit - 1001 US Patent No 10,335,462 (P.T.A.B. Mar. 1, 2024)
|
|
Cite Document
1036 Exhibit: 1036 Mojsov, Insulinotropin Glucagon like Peptide I 7 37 Co encoded...
Document
IPR2024-00631, No. 1036 Exhibit - 1036 Mojsov, Insulinotropin Glucagon like Peptide I 7 37 Co encoded in t (P.T.A.B. Mar. 1, 2024)
|
|
Cite Document
1023 Exhibit: 1023 Drucker, Enhancing Incretin Action for the Treatment of Type 2 ...
Document
IPR2024-00631, No. 1023 Exhibit - 1023 Drucker, Enhancing Incretin Action for the Treatment of Type 2 Diabete (P.T.A.B. Mar. 1, 2024)
|
|
Cite Document
1053 Exhibit: 1053 Møller, Mechanism Based Population Modelling for Assessment...
Document
IPR2024-00631, No. 1053 Exhibit - 1053 Møller, Mechanism Based Population Modelling for Assessment of L Cell (P.T.A.B. Mar. 1, 2024)
|
|
Cite Document
1035 Exhibit: 1035 Lund, Emerging GLP1 Receptor Agonists, 16 EXPERT OP ON...
Document
IPR2024-00631, No. 1035 Exhibit - 1035 Lund, Emerging GLP1 Receptor Agonists, 16 EXPERT OP ON EMERGING DRUG (P.T.A.B. Mar. 1, 2024)
|
|
Cite Document
1020 Exhibit: 1020 Bydureon prescribing information Jan 2012
Document
IPR2024-00631, No. 1020 Exhibit - 1020 Bydureon prescribing information Jan 2012 (P.T.A.B. Mar. 1, 2024)
|
|
Cite Document
1022 Exhibit: 1022 Drab, Incretin Based Therapies for Type 2 Diabetes Mellitus Cur...
Document
IPR2024-00631, No. 1022 Exhibit - 1022 Drab, Incretin Based Therapies for Type 2 Diabetes Mellitus Current S (P.T.A.B. Mar. 1, 2024)
|
|
Cite Document
1085 Exhibit: 1085 ACS Publications, httpspubsacsorgtocjmcmar4717 httpspubs
Document
IPR2024-00631, No. 1085 Exhibit - 1085 ACS Publications, httpspubsacsorgtocjmcmar4717 httpspubs (P.T.A.B. Mar. 1, 2024)
|
|
Cite Document
1044 Exhibit: 1044 Rohatagi, Model Based Development of a PPARγ Agonist, Rivog...
Document
IPR2024-00631, No. 1044 Exhibit - 1044 Rohatagi, Model Based Development of a PPARγ Agonist, Rivoglitazone, t (P.T.A.B. Mar. 1, 2024)
|
|
Cite Document
1505 Exhibit: 1505 Declaration of Hugh DC Smyth, PhD
Document
IPR2024-00631, No. 1505 Exhibit - 1505 Declaration of Hugh DC Smyth, PhD (P.T.A.B. Mar. 1, 2024)
|
|
Cite Document
1078 Exhibit: 1078 US Patent App Pub No 20040102486
Document
IPR2024-00631, No. 1078 Exhibit - 1078 US Patent App Pub No 20040102486 (P.T.A.B. Mar. 1, 2024)
|
|
Cite Document
